Birch Hill Investment Advisors LLC Sells 1,500 Shares of Pfizer Inc. (NYSE:PFE)

by · The Markets Daily

Birch Hill Investment Advisors LLC lessened its position in Pfizer Inc. (NYSE:PFE – Free Report) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,542 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the quarter. Birch Hill Investment Advisors LLC’s holdings in Pfizer were worth $768,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. LGT Group Foundation lifted its holdings in Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares in the last quarter. ORG Partners LLC lifted its holdings in Pfizer by 1,729.9% during the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. bought a new stake in Pfizer during the 1st quarter valued at about $2,439,000. Leo Wealth LLC bought a new stake in Pfizer during the 4th quarter valued at about $2,171,000. Finally, Commerzbank Aktiengesellschaft FI lifted its holdings in Pfizer by 29.1% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 342,361 shares of the biopharmaceutical company’s stock valued at $9,579,000 after buying an additional 77,073 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on PFE shares. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Check Out Our Latest Analysis on Pfizer

Pfizer Stock Performance

NYSE:PFE opened at $29.16 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a fifty day moving average of $29.04 and a two-hundred day moving average of $28.38. The stock has a market capitalization of $165.24 billion, a PE ratio of -486.00, a P/E/G ratio of 1.30 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.76%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).